Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
France
France- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
584 trials match your criteria
Recruiting
Bladder transitional cell carcinoma+1
RecruitingRegistered drug
A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer
Registered drug
- Disease:Bladder transitional cell carcinomaBladder cancer
- Substances:Enfortumab VedotinPembrolizumab+1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Enfortumab Vedotin
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
Recruiting
Focal segmental glomerulosclerosis
RecruitingInvestigational
A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)
Investigational
- Disease:Focal segmental glomerulosclerosis
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Countries:France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Recruiting
Sjogren's syndrome
RecruitingInvestigationalNo placebo
A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time
InvestigationalNo placebo
- Disease:Sjogren's syndrome
- Substances:Dazodalibep
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Dazodalibep
Recruiting
Asthma
RecruitingInvestigational
A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma
Investigational
Countries:France
France- Participants:18–64 years
- Substances:LY3537031
Recruiting
Cachexia
RecruitingInvestigational
A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is
Investigational
- Disease:Cachexia
- Substances:VISUGROMAB
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:VISUGROMAB
Recruiting
Vitiligo+2
RecruitingInvestigationalNo placebo
Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials
InvestigationalNo placebo
- Disease:VitiligoNeurodermatitis+1
- Substances:Povorcitinib4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Povorcitinib
Recruiting
Registered drugNo placebo
Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AnastrozoleCyclophosphamide+10
Countries:France
France- Participants:18–64 years
- Substances:Anastrozole
Recruiting
Cardiovascular disorder+2
RecruitingRegistered drug
Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease
Registered drug
- Disease:Cardiovascular disorderType 2 diabetes mellitus+1
- Substances:Bi 690517Empagliflozin
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Bi 690517
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
Investigational
- Disease:Arteriosclerosis
- Substances:–
Countries:France
France- Participants:18–64 years · 65+ years
Recruiting
Oesophageal squamous cell carcinoma
RecruitingRegistered drugNo placebo
Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Registered drugNo placebo
- Disease:Oesophageal squamous cell carcinoma
- Substances:DocetaxelPaclitaxel+2
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Docetaxel